TD Asset Management Inc Reduces Holdings in Kymera Therapeutics, Inc. $KYMR

TD Asset Management Inc lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 10.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 209,248 shares of the company’s stock after selling 25,722 shares during the period. TD Asset Management Inc owned 0.29% of Kymera Therapeutics worth $11,843,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. PNC Financial Services Group Inc. lifted its stake in Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the last quarter. Bessemer Group Inc. raised its stake in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Kymera Therapeutics in the 2nd quarter valued at about $73,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Kymera Therapeutics during the 2nd quarter worth about $116,000.

Kymera Therapeutics Stock Down 3.9%

Shares of Kymera Therapeutics stock opened at $91.35 on Monday. Kymera Therapeutics, Inc. has a 12-month low of $19.44 and a 12-month high of $103.00. The stock’s fifty day moving average is $78.52 and its 200-day moving average is $65.62. The firm has a market capitalization of $7.46 billion, a PE ratio of -24.82 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same period in the previous year, the firm posted ($0.88) earnings per share. The firm’s quarterly revenue was down 60.8% on a year-over-year basis. Analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera announced its degrader candidate KT‑579 has entered first‑in‑human (Phase 1) testing — an important de‑risking milestone that validates the Pegasus platform and expands the company’s clinical-stage pipeline. Article Title
• Positive Sentiment: Management reported a large cash infusion (~$1.6B) that materially extends the company’s cash runway into 2029 and supports planned development (including KT‑621), reducing near‑term dilution risk. This funding, combined with ongoing program progress, is a key positive for valuation and execution. Article Title
• Positive Sentiment: Analyst sentiment remains constructive: Piper Sandler raised its price target to $140 and the consensus analyst posture is still broadly a “Buy,” supporting potential upside from upgrades and model revisions. Article Title
• Neutral Sentiment: Kymera reiterated plans to read out KT‑621 Phase IIb data in 2027 — a clear catalyst for 2027 but distant; this keeps the company in a development‑stage timeline where interim updates will matter to sentiment. Article Title
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.97) vs. consensus ($0.77) and revenue of $2.87M vs. $14.8M (down ~60% y/y). The larger loss and revenue shortfall triggered near‑term selling and raises questions on near‑term commercial/collaboration cadence. Article Title
• Negative Sentiment: Insider selling: CEO Nello Mainolfi sold 30,000 shares (~$2.7M). While not uncommon for executives to monetize, multiple recent sales may weigh on investor sentiment in the short term. Article Title

Insider Transactions at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $89.76, for a total transaction of $448,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the completion of the transaction, the chief executive officer owned 666,195 shares in the company, valued at $60,130,760.70. The trade was a 4.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 450,895 shares of company stock valued at $40,486,151 in the last three months. 16.01% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Leerink Partners upped their price objective on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. HC Wainwright increased their price target on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Oppenheimer raised their price target on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. Guggenheim began coverage on Kymera Therapeutics in a report on Monday, November 3rd. They set a “buy” rating and a $90.00 target price for the company. Finally, B. Riley Financial lifted their price objective on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $117.60.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.